Reimbursement strategy
Toronto, February 18, 2020 – MORSE Consulting is pleased to expand and strengthen our service offering with the addition of Anita Carrie and Roy Cairns. Affordability of effective and innovative medications within the current Canadian public funding model is becoming very challenging for the healthcare system. Increasing budgetary constraints coupled with complex treatments requiring consideration of different sources and levels of evidence are an issue for all stakeholders. To help…
The 2019 Real-World Evidence and Outcomes-Based Agreements Working Group research and outputs executive summary report is now available. The mission of the Real-World Evidence and Outcomes-Based Agreements Working Group is to advance the opportunity for the use of outcomes-based agreements in Canada.
Toronto, September 18, 2019 – MORSE Consulting is pleased to launch the Canadian Reimbursement Trends and Timelines report – a comprehensive, credible and relevant source of market access intelligence. The market access pathway in Canada is going through an unprecedented level of change and uncertainty. This 58-page PowerPoint report is aimed at not only helping market access professionals plan for future launches but can be a valuable education tool for…
MORSE Consulting is pleased to release a new report entitled Spotlight on the Atlantic Provinces: pCPA Letter of Intent Conversion and Time-to-Listing Analysis. While the majority of Canadians have some form of prescription medication coverage, the speed and extent to which individual patients gain access to new therapies, can vary significantly. As new drugs (and expanded indications for existing drugs) are approved by Health Canada and become available for use…
Toronto, December 13, 2018 – Neil Grubert and MORSE Consulting are pleased to announce the release of a new report entitled Pharmaceutical Managed Entry Agreements – Lessons Learned from Europe, the United States, Canada, and Australia. A performance or outcomes-based agreement (OBA) tracks the effectiveness of a drug in a defined patient population over a specified period of time and directly links the price or reimbursement of the product to…
On November 27, 2018 the BC Ministry of Health changed coverage of glatiramer products, GLATECT™ and COPAXONE®, which demonstrates a shift from previous public drug plan approaches for funding of subsequent entry products (biosimilars) for chronic diseases. Background GLATECT™ is the first subsequent entry glatiramer-based treatment available for reimbursement for RRMS in Canada – i.e. a follow on product to Copaxone®. It is classifed as a non-biological complex…
Toronto, October 9, 2018 –MORSE Consulting is pleased to announce the addition of Anita Gadhok as Senior Consultant. With more than 20 years of experience, Anita has worked with provincial drug programs, cancer agencies, private insurance, and community pharmacies in both Ontario and Manitoba. She has been involved in a number of ground-breaking initiatives including precursor work to support the development of the pan-Canadian Oncology Drug Review (pCODR), evaluation framework…
Toronto, February 7, 2018: Cornerstone Research Group and MORSE Consulting are pleased to announce the creation of a strategic partnership between our two organizations. This strategic partnership will simplify the logistical process for our clients utilizing our combined services when shepherding a product from reimbursement strategy, to CADTH submission and finally to pCPA negotiations. Together the collaboration between Cornerstone and MORSE offers clients a breadth of reimbursement consulting services…
Toronto, October 16, 2017 – Sherry O’Quinn and Arvind Mani are very pleased to announce that Lorraine Boyle has joined the MORSE team as a Senior Advisor. Lorraine is a former registered nurse with over 25 years of experience in the Canadian public health care system and pharmaceutical and biotechnology industry. Her experience spans sales, marketing, market access, government relations and patient advocacy. Therapeutic areas of experience and expertise include nephrology,…
Toronto, May 1, 2017 – Arvind Mani and Sherry O’Quinn are pleased to announce a strategic partnership with Brent Korte of Impact Consulting as well as to welcome a new MORSE team member, Avery Hughes as a Reimbursement Strategist. Brent Korte has more than 25 years of experience in pharmaceutical industry and consulting with both national and regional expertise in health policy government relations, market access, strategy development and implementation expertise…
Contact Us
MORSE Consulting Inc.
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
Reimbursement strategy - Info and details on - Page 2 of 2 - MORSE Consulting Inc.
